Table 3

The relationship between the classical prognostic factors and amount of CK19+a cells in BM and PB (B-1) samples of BC patients

EffectNumber of casesLog CK19 (BM)Log CK19 [PB (B-1)]
Mean (SD)P valueMean (SD)P value
Pathological stage0.88580.8180
 I186.42 (2.08)5.33 (1.61)
 IIA186.42 (1.86)4.62 (2.26)
 IIB105.76 (1.23)4.60 (1.44)
 IIIA66.00 (1.44)5.07 (2.08)
 IIIB26.58 (0.65)5.22 (1.65)
Grade of differentiation0.59390.7532
 I76.80 (1.72)4.45 (1.72)
 II246.03 (1.79)5.05 (1.87)
 III236.31 (1.72)4.99 (1.93)
Positive nodes0.09040.8798
 0316.65 (1.88)5.04 (2.05)
 1–3145.35 (1.41)4.78 (1.46)
 >396.20 (1.19)4.74 (1.70)
Estrogen receptors0.27760.7052
 Positive376.07 (1.79)4.87 (1.93)
 Negative136.65 (1.60)5.09 (1.70)
Progesterone receptors0.52300.8376
 Positive366.37 (1.66)4.90 (1.84)
 Negative146.04 (1.89)5.02 (1.94)
  • a CK19, cytokeratin 19; BM, bone marrow; PB (B-1), peripheral blood before surgery; BC, breast cancer.